Results 91 to 100 of about 3,056 (181)

Cost-Effectiveness of Donanemab and Lecanemab Over a Lifetime Horizon for Patients with Early Alzheimers Disease

Background: Donanemab was recently approved following the 2023 approval of lecanemab for early Alzheimers disease (AD). While both therapies represent important advances in disease-modifying treatments, substantial concerns remain regarding their ...
Wu, Jun, Lv, Gang, Burroughs, Amber, Jiang, Xiangxiang, Yuan, Jing, Lu, Kevin   +5 more
core  

Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION We aimed to determine the clinical efficacy of treating apolipoprotein E (ApoE) ε4 homozygotes with recently approved anti‐amyloid antibodies. METHODS Data were derived from supplementary analyses in the regulatory studies Clarity (lecanemab)
Stefan Teipel, Yi Tang, Ara Khachaturian
doaj   +1 more source

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6

The Journal of Prevention of Alzheimer's Disease
The TRAILBLAZER-ALZ 6 study (NCT05738486) evaluated the effect of different donanemab dosing regimens on amyloid-related imaging abnormalities with edema/sulcal effusions (ARIA-E).
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, Emily C. Collins, Stephen Salloway, Mark A. Mintun, John R. Sims   +13 more
doaj   +1 more source

Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study

Purpose To evaluate changes in amyloid burden on serial amyloid PET before and after donanemab treatment in a real-world clinical cohort.
Yoichi Otomi, Tomoyasu Matsubara, Masahito Nakataki, Masafumi Harada, Yuishin Izumi, Yukiko Takaoka, Takayoshi Shinya, Hiroto Kasai, Tomoki Matsushita, Hideki Otsuka, Yukiko Tomioka, Shusuke Numata, Koji Fujita, Yuka Hiroshima   +13 more
core   +1 more source

Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic

The Journal of Prevention of Alzheimer's Disease
Lecanemab and donanemab are the first anti-Aβ treatments to receive approval in Europe. Eligibility criteria are strict, eg., APOE ε4/4 carriers are excluded.
Anna Rosenberg, Alina Solomon, Alexandre Bonnard, Makrina Daniilidou, Göran Hagman, Anette Hall, Anna Matton, Ulf Öhlund-Wistbacka, Eric Westman, Miia Kivipelto   +9 more
doaj   +1 more source

Donanemab in the Treatment of Alzheimer’s Disease: A Comprehensive Review

Journal of Multidisciplinary Health and Innovative Technology
Donanemab is a novel investigational monoclonal antibody developed by Eli Lilly, targeting pyroglutamate-modified amyloid-β (Aβ) plaques, a hallmark of Alzheimer’s disease (AD). It represents one of the most promising disease-modifying therapies for early symptomatic AD.
Ganna Anitha, K. Janarthanan, R. Hiruthikkrishnane, S. Ezhilarasan, P. Guneshwar, R. Harish   +5 more
openaire   +1 more source

Comparisons of efficacy and safety of immunotherapies for Alzheimer’s disease treatment: A network meta-analysis of randomised controlled trials

Clinical Medicine
Background: Alzheimer’s disease (AD) remains a major challenge due to limited effective therapies. Moreover, direct comparisons between newly developed and symptomatic drugs are lacking. This network meta-analysis aimed to compare the efficacy and safety
Ching-Hui Su, Ying-Tzu Chang, Huan-Shu Tseng, Chan-Yen Kuo, Jin-Hua Chen, Po-Yu Chien, Yao-Jen Chang, Chin-Chuan Hung   +7 more
doaj   +1 more source

Donanemab-associated clinical improvement in Alzheimer's disease presenting predominantly with neuropsychiatric symptoms: A case report

Late-life depression may mask Alzheimer's disease (AD). We report a 78-year-old man with treatment-refractory depressive and anxiety symptoms accompanied by paroxysmal somatic attacks, unresponsive to psychotropic treatment and modified electroconvulsive
Huamei Lin, Ling Yue, Yehao Jiang, Bo Hong   +3 more
core   +1 more source

Aggregation-dependent epitope sequence and modification fingerprints of anti-Aβ antibodies

eLife
A hallmark of Alzheimer’s disease (AD), the most common form of dementia, is the progressive accumulation of amyloid-beta (Aβ) peptides across distinct brain regions.
Ivan Talucci, Timon Leske, Hans-Wolfgang Klafki, Mohammed Mehedi Hassan, Annik Steiert, Barbara Morgado, Sebastian Bothe, Lars van Werven, Thomas Liepold, Jochen Walter, Hermann Schindelin, Jens Wiltfang, Oliver Wirths, Olaf Jahn, Hans Michael Maric   +14 more
doaj   +1 more source

Taking Donanemab as an Example: A Discussion on the Treatment of Alzheimer’s Disease (AD) with Second-Generation Anti-Aβ Monoclonal Antibodies

Alzheimer’s Disease (AD) is the most common form of dementia in older adults. The high incidence and high rate of disability put a heavy burden on patients' families and society.
Xiaoxuan Kan
core   +1 more source